-+ 0.00%
-+ 0.00%
-+ 0.00%

Health Canada accepts GSK Jemperli review for dMMR/MSI-H locally advanced rectal cancer

PUBT·09/24/2026 12:01:19
Listen to the news
Health Canada accepts GSK Jemperli review for dMMR/MSI-H locally advanced rectal cancer
  • Health Canada accepted GSK’s Jemperli for review in previously untreated stage II-III dMMR/MSI-H locally advanced rectal cancer.
  • Filing uses the accelerated NOC/c pathway, reviewed via the Project Orbis collaborative oncology program.
  • Submission backed by phase II AZUR-1 data showing sustained complete responses at 12 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via CNW (Ref. ID: 202609240800CANADANWCANADAPR_C1699) on September 24, 2026, and is solely responsible for the information contained therein.